ANZCTR search results

This is a multisite cluster randomized clinical trial of 300 patients across six clinical units in three tertiary acute hospitals to evaluate the clinical effectiveness of a pressure injury clinical judgement risk-screening and care planning tool in reducing pressure injuries. Standard care involves using the Waterlow pressure injury risk screening tool to determine a patient’s level of risk to develop a pressure injury. The intervention involves removing the Waterlow tool and using the pressure injury clinical judgement risk-screening and care planning tool. Our hypothesis is patients who receive the intervention have a lower incidence of HAPI compared to those patients who receive standard of care. The planned duration of this study is 12 months.

The most extensively investigated and characterised biomarker for in vivo imaging of neuroinflammation is the 18-kDa translocator protein (TSPO). Upregulation of TSPO expression, as visualised and quantified in vivo, has been associated with inflammation in common CNS disorders such as stroke, multiple sclerosis and Alzheimer’s disease. This study proposes to investigate whether PET imaging of TSPO radioligand [18F]GE-180 will serve as a robust diagnostic tool to predict neurlogical outcomes following spinal cord injury.

This trial is designed to assess the validity, reliability and responsiveness of an activity monitor, free walking app, ODI walk item, PFS and self-paced walking test

The purpose of this study is to determine if an extended use of a chemotherapy medication (temozolomide) after radiation improves survival outcome in patients with newly diagnosed brain cancer (also called a glioblastoma). Who is it for? You may be eligible for this study if you are an adult who has been diagnosed with a glioblastoma. Study details Participants will take part in one of two treatment options: - In treatment 1, participants will continue with their usual care. - In treatment 2, participants will receive an additional six cycles of chemotherapy for 5 days, with each cycle lasting 28 days. The treatment that participants receive will be decided randomly. Participants enrolled into treatment option 2 will undergo routine blood tests prior to the administration of chemotherapy as per their standard care It is hoped that this research will determine if temozolomide is effective in increasing the overall survival rates, as well as the duration of survival of participants with glioblastoma.

The purpose of this study is to test the feasibility and effectiveness of conducting a nutrition intervention with patients experiencing chronic pain who attend Hunter Integrated Pain Service. Hypothesis: Participants who receive the personalized dietary advice and high anthocyanin concentration fruit juice will have a greater reduction in pain scores compared to those randomized to the waitlist control plus placebo fruit juice group.

Hepatitis C virus (HCV) infection has itself been associated with impaired neuropsychological performance. Up to 50% of people diagnosed with HCV have reported neuropsychiatric disorders and neurocognitive dysfunction. People with schizophrenia, schizoaffective disorder and bipolar disorder suffer disproportionately high rates of HCV-infection. We hypothesis, that successful HCV treatment with DAA-based therapy is associated with improved neurocognitive function in people with severe mental illness. This may be particularly important for patients’ overall functioning and for quality of life in this marginalised and understudied population.

The study will test whether a device can detect OKN in children. The purpose of this study is that it is important in the development of a device that can detect vision problems in children.

This longitudinal study is an extension of the Oral Ketamine Trial on Suicidality. This study is an open-label, dose-ranging clinical trial of oral ketamine. Treatment will involve administration of oral ketamine over a 12-week period for Phase 1 (OKTOS-E) and over 26 weeks for Phase 2 (OKTOS-M). The pathology and neurobiology of suicidality will be examined via MRI and EEG as neurological measures. The primary outcome of change in suicidality will be assessed using the Beck Scale for Suicide Ideation (BSS) and the Suicidal Ideation Attributes Scales (SIDAS) as a composite outcome

The only treatment (intravenous immunoglobulin) shown to be effective in MMN and some patients with MADSAM is expensive and may not slow the long-term decline in physical ability (function). Bacille Calmette Guerin (BCG) vaccine is an intradermal (injected just beneath the skin) vaccine used to prevent tuberculosis; BCG has many effects on the immune system and may have a beneficial effect on the underlying mechanisms of MMN and MADSAM. The purpose of this trial is to study the safety and potential effectiveness of BCG in MMN and MADSAM. We hypothesise that BCG will be a therapeutic option that is safe and will improve outcomes (symptoms and physical ability) in MMN and MADSAM.

Reading impairment (dyslexia) is the most common specific learning difficulty in Australia. Approximately 10% of Australian children have substantial difficulties in reading and spelling, and these children are at elevated risk of developing mental health problems: both internalising disorders (e.g. anxiety, depression) and externalising disorders (e.g. attention and conduct problems, delinquency). The transition from primary to secondary school is a particularly stressful period for children with dyslexia, due to the increased educational demands and expectations placed on children regarding quantity and quality of reading and writing. We will conduct a pilot randomised controlled trial to test the efficacy of a mental health promotion program (Clever Kids) in improving coping, emotion regulation, resilience, self-esteem, as well as both internalising and externalising symptoms for children with dyslexia in their final two years of primary school. Acceptability and feasibility of the program will be assessed using in depth qualitative interviews with program attendees. The research will be conducted in partnership with the Dyslexia-SPELD Foundation (DSF).